NFKB1 and fatty liver disease: Rg1 reduces ALT/AST levels and pro-inflammatory cytokines, and effectively reduces hepatic steatosis and inflammation, which may be related to the AMP-activated protein kinase (AMPK)/NF-κB pathway (Xiao Q. et al., 2019).